PILL:NYE-Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (USD)

ETF | Trading--Leveraged Equity |

Last Closing

USD 7.78

Change

-0.11 (-1.39)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-21 )

Largest Industry Peers for Trading--Leveraged Equity

Symbol Name Price(Change) Market Cap
SOXL Direxion Daily Semiconductor B..

-2.89 (-9.12%)

USD 9.27B
QLD ProShares Ultra QQQ

-4.92 (-4.17%)

USD 8.27B
FNGU MicroSectors FANG+ Index 3X Le..

-56.98 (-8.78%)

USD 8.18B
SSO ProShares Ultra S&P500

-3.44 (-3.46%)

USD 5.76B
UPRO ProShares UltraPro S&P500

-5.07 (-5.17%)

USD 4.34B
TECL Direxion Daily Technology Bull..

-8.05 (-8.25%)

USD 3.09B
YINN Direxion Daily FTSE China Bull..

+1.81 (+4.19%)

USD 1.89B
USD ProShares Ultra Semiconductors

-5.05 (-7.44%)

USD 1.16B
UDOW ProShares UltraPro Dow30

-5.44 (-5.22%)

USD 0.77B
LABU Direxion Daily S&P Biotech Bul..

-3.42 (-3.62%)

USD 0.77B

ETFs Containing PILL

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Leveraged Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.58% 66% D+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.58% 66% D+ 88% B+
Trailing 12 Months  
Capital Gain -18.28% 14% F 12% F
Dividend Return 0.82% 37% F 11% F
Total Return -17.46% 12% F 11% F
Trailing 5 Years  
Capital Gain -69.87% 20% F 6% D-
Dividend Return 1.08% 16% F 3% F
Total Return -68.78% 17% F 5% F
Average Annual (5 Year Horizon)  
Capital Gain 57.42% 79% B- 95% A
Dividend Return 58.00% 79% B- 94% A
Total Return 0.58% 41% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 392.95% 15% F 3% F
Risk Adjusted Return 14.76% 25% F 30% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.